Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

August 4, 2025 2:10 PM EDT

TD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).

The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More

Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush

August 4, 2025 1:24 PM EDT

Wedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.

The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More

Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

August 4, 2025 12:58 PM EDT

Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $155.00 (from $120.00) while maintaining a Buy rating.

The analyst comments "Key Message: In the open-label RADIANT study (n=37), vormatrigine demonstrated an impressive 56.3% reduction in monthly seizure frequency... More